IGF::OT::IGF SBIR PHASE II TOPIC 62, STRATEGY FOR FINDING CASES OF MODERATE-TO-SEVERE COPD

这是一份与国家心肺血液研究所签订第二阶段SBIR合同的提案 成熟和扩展电子开源筛选工具ScreenFlow的功能 适用于有中到重度COPD风险的患者。总体目标是提供一种手段来 筛查和诊断更多的COPD病例，允许更早和更多的病例 干预和治疗。 ScreenFlow平台是通过第一阶段SBIR合同开发和验证的。 通过这个拟议的二期项目，平台将得到改进和进一步验证 通过一系列关于其目标部署的研究，其中包括1)初级保健诊所 由医疗助理提供，2)医院的公共区域作为独立的筛查 工具。该项目的成果衡量标准包括通过可用性研究获得的定性数据，以及 定量数据，如对照肺活量测定黄金标准的ROC发展情况。 该项目的主要合作伙伴将保持与SBIR第一阶段相同，波士顿医疗 中心(BMC)作为临床合作伙伴。DImagi是一家将专业知识带到 在SBIR赠款和合同方面的技术开发和经验。

This is a proposal for a Phase II SBIR contract with the National Heart, Lung and Blood Institute to mature and expand the capabilities of ScreenFlow, an electronic open source screening tool for patients with moderate to severe risk for COPD. The overall aim is to provide a means to screen and diagnose more cases of COPD, allowing for earlier and increased instances of intervention and treatment. The ScreenFlow platform was developed and validated through a Phase I SBIR contract. Through this proposed Phase II project, the platform will be improved and further validated through a series of studies with its target deployments, which include 1) a primary care clinic as delivered by medical assistants and 2) a public area of a hospital as a stand-alone screening tool. Outcome measures of this project include qualitative data through usability studies, and quantitative data such as the development of an ROC against the gold standard of spirometry. The primary partners on this project will remain the same as SBIR Phase I, with Boston Medical Center (BMC) as the clinical partner. Dimagi is the small business that brings expertise in the technology development and experience in SBIR grants and contracts.